Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01927731 · ClinicalTrials.gov registry record · Phase 2

Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target

NCT01927731: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT01927731 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01927731, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target

Study Summary

This phase II trial studies how well eltrombopag olamine works in increasing platelet counts in patients undergoing transplant. Eltrombopag olamine may help platelet counts and the immune system recover from blood or bone marrow transplant.

Primary Outcome

Number of participants that achieved platelet engraftment greater than 50K/ul 60 days post transplant.

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Eltrombopag Olamine

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2013-10-14
Est. Completion 2023-06-06
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT01927731 record still lists

NCT01927731 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).

The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT01927731 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01927731 about?

NCT01927731 is a clinical study titled "Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant". This phase II trial studies how well eltrombopag olamine works in increasing platelet counts in patients undergoing transplant. Eltrombopag olamine may help platelet counts and the immune system recover from blood or bone marrow transplant.

What is the current status of trial NCT01927731?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2013-10-14. Estimated completion is 2023-06-06.

What interventions are being tested in trial NCT01927731?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Eltrombopag Olamine (DRUG).

Who is sponsoring clinical trial NCT01927731?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01927731's enrollment target sits among peer trials

48 1265th of 2000 higher than 718 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01927731, the US trial registry maintained by the National Library of Medicine. NCT01927731 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.